Drug Profile
AEG 40826
Alternative Names: AEG40826; HGS-1029Latest Information Update: 20 May 2016
Price :
$50
*
At a glance
- Originator Aegera Therapeutics
- Developer Human Genome Sciences; Pharmascience
- Class Antineoplastics; Small molecules
- Mechanism of Action Inhibitor of apoptosis protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
- Discontinued Lymphoma
Most Recent Events
- 20 May 2016 No recent reports on development identified- Phase-I for Solid tumours in Canada (IV)
- 12 Dec 2012 Pharmascience intends to initiate a phase Ib trial of AEG 40826 in the near future
- 12 Dec 2012 Pharmascience Inc. regains global rights to AEG 4086 as part of an agreed-upon termination of its oncology collaboration with Human Genome Sciences